Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Sarah Blagden, Skirmantas Kriaucionis and their collaborators who have been awarded funding in the third round of the OxCODE Funding Scheme.

The Oxford Centre for Early Cancer Detection (OxCODE) Funding Scheme aims to advance innovative Oxford-based research that can be applied to detecting cancer earlier. OxCODE provides short-term awards that will enable the development of proof-of-concept projects, technologies, assays and platforms to a stage at which more long-term external funding can be sought. Priority was given to projects with a clear translational trajectory towards the ultimate longer-term goal of improving cancer patient care through earlier detection.

After peer review by the OxCODE Operational Group and Oxford Cancer Patient and Public Involvement group, funds were allocated to the following projects:

  • Professor Sarah Blagden (Department of Oncology) “Defining the immunopeptidomic landscape of ovarian cancer”.
  • Professor Skirmantas Kriaucionis (Ludwig Institute for Cancer Research) “A pilot study to investigate prognostic biomarkers in patients with non-muscle invasive bladder cancer (NMIBC)”

Congratulations to these teams and thank you to all applicants for their submissions.

 

Similar stories

Oxford research contributes to new guidelines on faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer

The joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) provides a clear strategy for the use of FIT in the colorectal cancer diagnostic pathway.

Blood tests provide no additional information to FIT alone when prioritising patients for colorectal cancer referral

Faecal immunochemical testing (FIT) alone leads to the identification of the same number of patients with colorectal cancer as more complicated approaches that combine the FIT result with the results of commonly used blood tests.